Braemar Hotels & Resorts: Internalizing Management
Braemar Hotels & Resorts is internalizing its management.
Blog
Clark Street Value
Everything we have picked from this writer, newest first.
Investcorp Credit Management BDC: Visiting the Private Credit Garbage Bin
Investcorp Credit Management BDC is framed as a troubled corner of private credit.
Theravance Biopharma: Failed Phase 3 Trial, Strategic Review
Theravance Biopharma began a strategic review after a failed Phase 3 trial.
Braemar Hotels & Resorts: HST Four Seasons Sale, Updated Thoughts
Braemar Hotels & Resorts’ Four Seasons sale prompts updated views on HST.
Green Dot: Creating a Standalone BaaS Bank
Green Dot creates a standalone banking-as-a-service bank.
Golden Entertainment: PropCo OpCo Split, Insufficient MBO Offer
Golden Entertainment’s PropCo-OpCo split follows an insufficient management buyout offer.
Sotherly Hotels: Buyout, Preferred Share Conversion Arbitrage
Sotherly Hotels buyout creates a preferred-share conversion arbitrage opportunity.
Braemar Hotels & Resort: Gross Asset Management Contract, Initiated Sales Process
Braemar Hotels & Resorts initiated a sales process and faces a gross asset management contract.
180 Degree Capital: Merger w/ Mount Logan Capital, Tender Offer, Questions Remain
180 Degree Capital plans to merge with Mount Logan Capital and launch a tender offer, leaving open questions around the transaction.
Mural Oncology: Update
Mural Oncology update.
Franklin Street Properties: Office Basket, Strategic Alternatives
Franklin Street Properties pursues strategic alternatives for its office-property portfolio.
Net Lease Office Properties: Office Basket, REIT Spin/Liquidation
Net Lease Office Properties is a REIT office basket pursuing a spin-off and liquidation.
GCI Liberty: Cheap, Tax Asset, Malone Fatigue?
GCI Liberty trades cheaply, holds tax assets, and faces investor fatigue with John Malone.
NSTS Bancorp: Post 3-Year Thrift Conversion, Possible Sale
NSTS Bancorp’s three-year thrift-conversion anniversary could clear the way for a potential sale.
Kronos Bio: Tang Buyout w/ Curious CVR Consideration
Kronos Bio’s Tang buyout includes a contingent value right with unusual consideration terms.
Repare Therapeutics: Broken Biotech, Hidden Strategic Alternatives
Repare Therapeutics faces a broken biotech valuation and potential strategic alternatives.
Mural Oncology: Former Spin Turned Broken Biotech
Mural Oncology is a former spin-off biotech now described as broken.
Elevation Oncology: Broken Biotech, Slightly Riskier
Elevation Oncology is a broken biotech with a slightly riskier setup.
Dun & Bradstreet: Strategic Process Wrapping Up, Cheap Valuation
Dun & Bradstreet’s strategic process is wrapping up as the company trades at a cheap valuation.
Third Harmonic Bio: Strategic Alternatives, Keeping Options Open on THB335
Third Harmonic Bio is pursuing strategic alternatives while preserving options for its THB335 program.
